• Home
  • About us
  • Team
    • Management team
    • Advisory Board
  • Portfolio companies
    • Exited investments
    • Current investments
  • News
  • Contact

News

Home / News

Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction

08.02.2018

Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction

More

Immusoft Recognized with “Most Promising Company Award” at Silicon Valley Conference

29.01.2018

In making its decision, the judging panel, consisting of leaders in venture capital and biotechnology, considered, among other attributes, the strength of Immusoft’s intellectual property, its ability to disrupt the current standard-of-care, as well as its commercialization strategy and expected value creation for shareholders.

More

Bonti Announces Close of $15.5 Million Series C Funding and Appointment of David Ramsay as Chief Financial Officer

23.01.2018

Latest Financing to Enable Continued Clinical Development of Lead Product EB-001 to Treat Musculoskeletal Pain

More

Immusoft raises $3M, appoints new CEO as it approaches clinical trials

05.01.2018

The funding is first part of the company’s ongoing Series B round.

More

Bonti to Present at Two Prestigious Healthcare Conferences

05.01.2018

Fauad Hasan, CEO and Co-founder, to Spotlight the Company in San Francisco.

More
Previous
Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11